PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
March 27, 2024 07:30 ET
|
PDS Biotechnology Corporation
Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to...
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
March 20, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing...
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
March 13, 2024 08:00 ET
|
PDS Biotechnology Corporation
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for...
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
January 22, 2024 16:45 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline...
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
January 16, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline...
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 16:50 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
November 28, 2023 07:30 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline...
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 07:30 ET
|
PDS Biotechnology Corporation
Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months...
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
November 09, 2023 08:00 ET
|
PDS Biotechnology Corporation
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months 12-month survival rate in ICI resistant...
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
November 07, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...